{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:08:35Z","timestamp":1773299315657,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Spinal Cord Ser Cases"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Individuals with spinal cord injury (SCI) experience alterations in metabolism that result in increased central obesity, insulin resistance, and dyslipidemia placing them at elevated risk for developing cardiometabolic disease (CMD). Increased exercise and dietary modifications are the primary interventions for preventing CMD. However, people with SCI face unique challenges that prevent them from increasing their physical activity and easily modifying their nutritional intake. Tirzepatide is a medication that has been approved by the Food and Drug Administration to be used in conjunction with lifestyle changes to treat obesity in adults with type 2 diabetes mellitus.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>A male in his 40\u2019s with C6 American Spinal Injury Association Impairment Scale B SCI 15 years prior with a body mass index of 32 presented to his primary care provider for treatment of obesity. He previously worked with multiple dietitians and increased his physical activity to lose weight. Despite these interventions, he was unable to reduce his weight. He was started on tirzepatide. After 3 months of treatment, he lost 31 pounds and saw improvements in his lipid profile. The only adverse effect reported was heartburn.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>The metabolic dysfunction associated with SCI and barriers to adequate exercise for weight loss place individuals with SCI at increased risk for obesity and developing CMD. Tirzepatide may be an effective adjunct therapy to lifestyle interventions to help prevent CMD in those with SCI. Further research is indicated to examine the long-term efficacy, benefits, and adverse effects that may be associated with tirzepatide.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41394-025-00699-w","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T17:43:11Z","timestamp":1740850991000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of obesity in spinal cord injury with tirzepatide: a case report"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4881-4546","authenticated-orcid":false,"given":"Michael","family":"Juszczak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9267-025X","authenticated-orcid":false,"given":"Kazuko","family":"Shem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,1]]},"reference":[{"key":"699_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/10790268.2009.11760749","volume":"32","author":"SL Groah","year":"2009","unstructured":"Groah SL, Nash MS, Ljungberg IH, Libin A, Hamm LF, Ward E, et al. Nutrient intake and body habitus after spinal cord injury: an analysis by sex and level of injury. J Spinal Cord Med. 2009;32:25\u201333.","journal-title":"J Spinal Cord Med"},{"key":"699_CR2","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1212\/WNL.0b013e3182a1ab26","volume":"81","author":"EV Kuklina","year":"2013","unstructured":"Kuklina EV, Hagen EM. Link between cardiovascular disease and spinal cord injury: new evidence and update. Neurology. 2013;81:700\u20131.","journal-title":"Neurology"},{"key":"699_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/sj.sc.3100351","volume":"35","author":"A Hartkopp","year":"1997","unstructured":"Hartkopp A, Br\u00f8nnum-Hansen H, Seidenschnur AM, Biering-S\u00f8rensen F. Survival and cause of death after traumatic spinal cord injury. A long-term epidemiological survey from Denmark. Spinal Cord. 1997;35:76\u201385.","journal-title":"Spinal Cord"},{"key":"699_CR4","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/sj.sc.3101729","volume":"43","author":"E Garshick","year":"2005","unstructured":"Garshick E, Kelley A, Cohen SA, Garrison A, Tun CG, Gagnon D, et al. A prospective assessment of mortality in chronic spinal cord injury. Spinal Cord. 2005;43:408\u201316.","journal-title":"Spinal Cord"},{"key":"699_CR5","unstructured":"Organization WH Facts Sheet Spinal Cord Injury Online: World Health Organization; 2013 [web page]. Available from: World Health Organization. Spinal Cord Injury. Accessed April 28, 2021. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/spinal-cord-injury."},{"key":"699_CR6","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","volume":"365","author":"RH Eckel","year":"2005","unstructured":"Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415\u201328.","journal-title":"Lancet"},{"key":"699_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ecl.2004.03.002","volume":"33","author":"G Reaven","year":"2004","unstructured":"Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am. 2004;33:283\u2013303.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"699_CR8","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/j.1559-4572.2009.00054.x","volume":"11","author":"EP Kirk","year":"2009","unstructured":"Kirk EP, Klein S. Pathogenesis and pathophysiology of the cardiometabolic syndrome. J Clin Hypertens (Greenwich). 2009;11:761\u20135.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"699_CR9","doi-asserted-by":"publisher","first-page":"3A","DOI":"10.1016\/j.amjcard.2005.11.010","volume":"97","author":"SM Haffner","year":"2006","unstructured":"Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol. 2006;97:3A\u201311A.","journal-title":"Am J Cardiol"},{"key":"699_CR10","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/10790268.2018.1511401","volume":"42","author":"MS Nash","year":"2019","unstructured":"Nash MS, Groah SL, Gater DR, Dyson-Hudson TA, Lieberman JA, Myers J, et al. Identification and management of cardiometabolic risk after spinal cord injury. J Spinal Cord Med. 2019;42:643\u201377.","journal-title":"J Spinal Cord Med"},{"key":"699_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/10790268.2017.1423266","volume":"42","author":"DR Gater","year":"2019","unstructured":"Gater DR, Farkas GJ, Berg AS, Castillo C. Prevalence of metabolic syndrome in veterans with spinal cord injury. J Spinal Cord Med. 2019;42:86\u201393.","journal-title":"J Spinal Cord Med"},{"key":"699_CR12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1242\/dmm.001180","volume":"2","author":"PL Huang","year":"2009","unstructured":"Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;2:231\u20137.","journal-title":"Dis Model Mech"},{"key":"699_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1310\/sci1903-183","volume":"19","author":"A Libin","year":"2013","unstructured":"Libin A, Tinsley EA, Nash MS, Mendez AJ, Burns P, Elrod M, et al. Cardiometabolic risk clustering in spinal cord injury: results of exploratory factor analysis. Top Spinal Cord Inj Rehabil. 2013;19:183\u201394.","journal-title":"Top Spinal Cord Inj Rehabil"},{"key":"699_CR14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.atherosclerosis.2013.11.028","volume":"232","author":"O Gilbert","year":"2014","unstructured":"Gilbert O, Croffoot JR, Taylor AJ, Nash M, Schomer K, Groah S. Serum lipid concentrations among persons with spinal cord injury - a systematic review and meta-analysis of the literature. Atherosclerosis. 2014;232:305\u201312.","journal-title":"Atherosclerosis"},{"key":"699_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.46292\/sci20-00067","volume":"27","author":"DR Gater","year":"2021","unstructured":"Gater DR, Farkas GJ, Tiozzo E. Pathophysiology of neurogenic obesity after spinal cord injury. Top Spinal Cord Inj Rehabil. 2021;27:1\u201310.","journal-title":"Top Spinal Cord Inj Rehabil"},{"key":"699_CR16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.46292\/sci20-00063","volume":"27","author":"PS Gordon","year":"2021","unstructured":"Gordon PS, Farkas GJ, Gater DR. Neurogenic obesity-induced insulin resistance and type 2 diabetes mellitus in chronic spinal cord injury. Top Spinal Cord Inj Rehabil. 2021;27:36\u201356.","journal-title":"Top Spinal Cord Inj Rehabil"},{"key":"699_CR17","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1093\/ajcn\/69.4.632","volume":"69","author":"S Yu-Poth","year":"1999","unstructured":"Yu-Poth S, Zhao G, Etherton T, Naglak M, Jonnalagadda S, Kris-Etherton PM. Effects of the national cholesterol education Program\u2019s step I and step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. Am J Clin Nutr. 1999;69:632\u201346.","journal-title":"Am J Clin Nutr"},{"key":"699_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.amjmed.2014.10.014","volume":"128","author":"RJ Widmer","year":"2015","unstructured":"Widmer RJ, Flammer AJ, Lerman LO, Lerman A. The mediterranean diet, its components, and cardiovascular disease. Am J Med. 2015;128:229\u201338.","journal-title":"Am J Med"},{"key":"699_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1079\/PHN2003481","volume":"6","author":"B Margetts","year":"2003","unstructured":"Margetts B. FAO\/WHO launch expert report on diet, nutrition and prevention of chronic diseases. Public Health Nutr. 2003;6:323\u20135.","journal-title":"Public Health Nutr"},{"key":"699_CR20","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1080\/10790268.2019.1592926","volume":"44","author":"P Iyer","year":"2021","unstructured":"Iyer P, Beck EJ, Walton KL. A systematic review of the effect of dietary interventions on cardiovascular disease risk in adults with spinal cord injury. J Spinal Cord Med. 2021;44:184\u2013203.","journal-title":"J Spinal Cord Med"},{"key":"699_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41393-018-0218-4","volume":"57","author":"GJ Farkas","year":"2019","unstructured":"Farkas GJ, Pitot MA, Berg AS, Gater DR. Nutritional status in chronic spinal cord injury: a systematic review and meta-analysis. Spinal Cord. 2019;57:3\u201317.","journal-title":"Spinal Cord"},{"key":"699_CR22","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/01.phm.0000171172.96290.67","volume":"84","author":"WM Scelza","year":"2005","unstructured":"Scelza WM, Kalpakjian CZ, Zemper ED, Tate DG. Perceived barriers to exercise in people with spinal cord injury. Am J Phys Med Rehabil. 2005;84:576\u201383.","journal-title":"Am J Phys Med Rehabil"},{"key":"699_CR23","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2165\/00007256-200434110-00003","volume":"34","author":"PL Jacobs","year":"2004","unstructured":"Jacobs PL, Nash MS. Exercise recommendations for individuals with spinal cord injury. Sports Med. 2004;34:727\u201351.","journal-title":"Sports Med"},{"key":"699_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.46292\/sci20-00058","volume":"27","author":"DW McMillan","year":"2021","unstructured":"McMillan DW, Maher JL, Jacobs KA, Nash MS, Gater DR. Exercise interventions targeting obesity in persons with spinal cord injury. Top Spinal Cord Inj Rehabil. 2021;27:109\u201320.","journal-title":"Top Spinal Cord Inj Rehabil"},{"key":"699_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.46292\/sci20-00035","volume":"27","author":"DW McMillan","year":"2021","unstructured":"McMillan DW, Nash MS, Gater DR, Valderr\u00e1bano RJ. Neurogenic obesity and skeletal pathology in spinal cord injury. Top Spinal Cord Inj Rehabil. 2021;27:57\u201367.","journal-title":"Top Spinal Cord Inj Rehabil"},{"key":"699_CR26","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1001\/jama.2016.7602","volume":"315","author":"R Khera","year":"2016","unstructured":"Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315:2424\u201334.","journal-title":"JAMA"},{"key":"699_CR27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331:38\u201348.","journal-title":"JAMA"},{"key":"699_CR28","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.2337\/dc23-1135","volume":"46","author":"MT Ma\u0142ecki","year":"2023","unstructured":"Ma\u0142ecki MT, Batterham RL, Sattar N, Levine JA, Rodr\u00edguez \u00c1, Bergman BK, et al. Predictors of \u226515% weight reduction and associated changes in cardiometabolic risk factors with tirzepatide in adults with type 2 diabetes in SURPASS 1-4. Diabetes Care. 2023;46:2292\u20139.","journal-title":"Diabetes Care"},{"key":"699_CR29","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/sj.sc.3101162","volume":"39","author":"SL Groah","year":"2001","unstructured":"Groah SL, Weitzenkamp D, Sett P, Soni B, Savic G. The relationship between neurological level of injury and symptomatic cardiovascular disease risk in the aging spinal injured. Spinal Cord. 2001;39:310\u20137.","journal-title":"Spinal Cord"},{"key":"699_CR30","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1212\/WNL.0b013e3182a1aa68","volume":"81","author":"JJ Cragg","year":"2013","unstructured":"Cragg JJ, Noonan VK, Krassioukov A, Borisoff J. Cardiovascular disease and spinal cord injury: results from a national population health survey. Neurology. 2013;81:723\u20138.","journal-title":"Neurology"},{"key":"699_CR31","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/PHM.0b013e31802f0247","volume":"86","author":"J Myers","year":"2007","unstructured":"Myers J, Lee M, Kiratli J. Cardiovascular disease in spinal cord injury: an overview of prevalence, risk, evaluation, and management. Am J Phys Med Rehabil. 2007;86:142\u201352.","journal-title":"Am J Phys Med Rehabil"},{"key":"699_CR32","first-page":"1043","volume":"102","author":"PF Raguindin","year":"2023","unstructured":"Raguindin PF, Mueller G, Stoyanov J, Eriks-Hoogland I, Jordan X, Stojic S, et al. Burden of cardiovascular risk in individuals with spinal cord injury and its association with rehabilitation outcomes: results from the swiss spinal cord injury cohort. Am J Phys Med Rehabil. 2023;102:1043\u201354.","journal-title":"Am J Phys Med Rehabil"},{"key":"699_CR33","first-page":"14","volume":"4","author":"RE Khalil","year":"2013","unstructured":"Khalil RE, Gorgey AS, Janisko M, Dolbow DR, Moore JR, Gater DR. The role of nutrition in health status after spinal cord injury. Aging Dis. 2013;4:14\u201322.","journal-title":"Aging Dis"},{"key":"699_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205\u201316.","journal-title":"N Engl J Med"},{"key":"699_CR35","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1001\/jama.2023.19574","volume":"330","author":"M Sodhi","year":"2023","unstructured":"Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 Receptor agonists for weight loss. JAMA. 2023;330:1795\u20137.","journal-title":"JAMA"},{"key":"699_CR36","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327:138\u201350.","journal-title":"JAMA"},{"key":"699_CR37","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397:971\u201384.","journal-title":"Lancet"}],"container-title":["Spinal Cord Series and Cases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41394-025-00699-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41394-025-00699-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41394-025-00699-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T17:43:14Z","timestamp":1740850994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41394-025-00699-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["699"],"URL":"https:\/\/doi.org\/10.1038\/s41394-025-00699-w","relation":{},"ISSN":["2058-6124"],"issn-type":[{"value":"2058-6124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,1]]},"assertion":[{"value":"22 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. With the patient\u2019s informed consent, information on this case report was extracted from his electronic medical records, and additional information was obtained from the patient. Additional ethical approval was not required per the local Institutional Review Board, because this report is a case report on one patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"4"}}